A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope
A year after her darkest day, Debra Miller found herself puzzling over a voicemail about potential research. The drugs behind that call were once fiercely debated by the FDA, but for patients like Debra, they may now offer a path forward.
21 hours ago
2 mins read
